Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

Executive Summary

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview the US Inflation Reduction Act, telehealth, interoperability of healthcare data, and Mark Cuban’s pharma venture.

You may also be interested in...

Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe

A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”

Medicare Drug Payment Demonstration May Advance In 2023 Under Executive Order

Demonstration would ‘build on’ Medicare price controls established by the Inflation Reduction Act, White House says.

Medicare Drug Price Control Group Formed At CMS: How Will Stakeholders Interact?

As the Centers for Medicare and Medicaid Services begins the process of building new price negotiation and inflation rebate programs within Medicare, stakeholders are watching to see how transparent the process will be and how much outside input the agency will seek.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts